U.S. FDA Commissioner Marty Makary said the agency wants to speed new drug trials by cutting the amount of data required to initiate studies in the U.S., removing most non-safety components from the start package. The plan aims to reduce administrative friction and bring earlier human testing into development. The announcement was framed as a strategy to maintain safety while streamlining trial start requirements, particularly as sponsors navigate complex preclinical documentation. The report suggests FDA is looking to accelerate development timelines without lowering the safety bar. For biotech, this is a practical regulatory signal: earlier trial initiation could affect how companies stage IND-enabling work and how they allocate resources between safety packages and non-safety evidence.